How Fulgent Genetics delivered 64% gains from undervalued entry
In March 2026, Fulgent Genetics (FLGT) was trading at $15.14 after a 41% monthly decline, prompting many investors to exit. However, InvestingPro's Fair Value analysis revealed a different story, indicating an intrinsic value of $22.58, implying a 49% upside from the entry price. Eight months later, the stock delivered a remarkable 64.13% return, validating the power of comprehensive valuation analysis.
Despite continued operational challenges, such as earnings misses and revenue shortfalls, the stock has managed to recover, currently trading at 77.7% of its 52-week high.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written; may contain errors — check the original.